



August 12, 2025

BSE Limited

Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

Scrip Code: **543271**

National Stock Exchange of India Limited

Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Trading Symbol: **JUBLINGREA**

Dear Sirs,

Sub: Intimation of Investors/ Analysts Meeting

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be meeting the following institutional investors in person on August 19 & August 20, 2025 at Sofitel BKC, Mumbai at Equirus Annual India Conference'25 organized by Equirus:

1. Edelweiss AMC
2. AXIS Mutual Fund
3. Bandhan Mutual Fund
4. HDFC Mutual Fund
5. ICICI Prudential Life Insurance Co Ltd
6. Kotak Mutual Fund
7. Trust Mutual Fund
8. Groww Mutual Fund
9. Kabouter Management LLC
10. Sundaram Mutual Fund
11. IKIGAI Asset Manager Holdings Pvt. Ltd
12. Svan Investments
13. Electrum Capital
14. Equirus PMS
15. Birla Life Insurance Co ltd
16. TATA Mutual Fund
17. Enam AMC
18. Omkara Capital
19. Kedaara Capital
20. Birla Mutual Fund
21. Monarch AIF
22. One Up Financial
23. NV Alpha

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657



The schedule may undergo change due to exigencies on the part of Investors / Analysts / Company.

We also enclose the presentation to be discussed during the meetings. This is for your information and record.

Thanking you,

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com


Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657




Investor Presentation

August 2025

Innovating for a Sustainable Future





Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

NOTES:

1. The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary
2. Closing Exchange Rate for USD 1 at Rs 85.76 as on June 30, 2025 and Rs 85.5 as on March 31, 2025.

Chairmen's Message on Q1'FY26 Financial Results | 1/2

"We are pleased to present the financial results for the first quarter of this fiscal year. Our specialty chemical businesses have continued to perform strongly, growing double digit YoY and with stable performance on QoQ basis. Our Chemical Intermediates business has started to recover marginally with QoQ growth. Ongoing cost optimization initiatives have further enhanced profitability, with EBITDA for the quarter rising by 29% YoY and Profit After Tax increasing by an impressive 54% YoY.

Markets Update:

*The **global chemicals sector** is emerging from the inventory destocking phase. Specialty chemicals are seeing volume growth, though pricing remains stable. Commodity segments continue to face demand challenges, with prices stabilizing at lower levels. **China +1 macro-trend** is creating more opportunities for us, especially in our specialty chemicals segment where we are witnessing healthy funnel across sub-segments.*

*The **Pharmaceutical end-use** market continues to show steady growth, driven by stable pricing and consistent volumes growth across various derivatives as well as Intermediates segments.*

*The **Agrochemical sector** continues its upward momentum, driven by strong volume growth both on YoY and QoQ basis. Average prices have been stable for last few quarters now.*

*The **Nutrition market** saw stable volumes during the quarter. Niacinamide demand remained muted as customers delayed purchases amid competitive offerings, while choline demand rose notably, with prices holding steady.*



Mr. Shyam S Bhartia

Chairman

&

Mr. Hari S Bhartia

Co-Chairman

Chairmen's Message on Q1'FY26 Financial Results | 2/2



Mr. Shyam S Bhartia
Chairman
&
Mr. Hari S Bhartia
Co-Chairman

Business Update:

Specialty Chemicals saw stable volumes, with growth led by Pyridine and Diketene derivatives and CDMO sales. Pharma end-use sales posted strong YoY demand growth with steady pricing. Agriculture end-use segment showed modest volume gains, stable pricing, and normalized inventories. CDMO volumes rose sharply on YoY basis, supported by proprietary agro and pharma order sales.

The Nutrition and Health Solutions Business segment witnessed substantial YoY volume growth, primarily fueled by significant increases in Cosmetic-grade demand, with new cGMP facility receiving exceptional response. Feed volumes remained low due to cautious buying by the customers, with marginal price softening. Choline products saw sustained YoY growth, and the EU's anti-dumping duty on China is expected to strengthen Jubilant's position in Choline Chloride market. We are already in touch with multiple EU customers for choline chloride sales.

In Chemical Intermediates segment, our strategic push towards Ethyl Acetate, led to a YoY increase in volumes. Acetic Anhydride volumes also recovered sequentially, with marginal uptick in demand from Agrochem sector. Overall, pricing in the segment stayed relatively muted. We continued with our cost focus in this quarter to improve the margins vs. last quarter.

Future Outlook:

For FY26, we anticipate continued growth and improved performance, driven by advancements in our Specialty Chemicals and Nutrition businesses, and expected recovery in Acetyls portfolio. Alongside we remain committed towards our Lean 2.0 cost efficiency initiatives. We are on track to deliver the big CDMO order in early 2026, which should further accelerate our growth trajectory in coming quarters."

Table of Contents

06

Company Overview



13

Growth Roadmap



18

Q1'FY26 Highlights



25

Business Segments Update




Company Overview



Visuals of our New Diketene Derivatives Plant in Gajraula

JVL has a rich legacy spread over the last 45 years and 4 major chapters



3 business verticals: Specialty Chemicals, Nutrition & Health Solution, and Chemical Intermediates



1

Specialty Chemicals

- CDMO
- Fine Chemicals
- Pyridine and Picolines

Globally #1

- Bio-Pyridine,
- Bio Beta Picoline
- 36 Pyridine Derivatives

2

Nutrition & Health Solutions

- Animal Nutrition and Health Solutions
- Human Nutrition Solutions

Globally #2

in Vitamin B3

Domestic leader

in Vitamin B4

3

Chemical Intermediates


- Acetic Anhydride
- Acetaldehyde
- Ethyl Acetate
- Bio Acetic Acid

Globally #2

in Acetic Anhydride
Merchant Market


Specialty Chemicals and Pharma are biggest revenue contributors while exports constitute >40% of business

Business wise Split
Q1'FY26




Specialty Chemicals and Nutrition
contribute >60% of revenues

Application wise Split
Q1'FY26



Pharma and Nutrition
are the biggest contributors
with ~53% of revenue

Geography wise Split
Q1'FY26



North America, & EU
drive >30% of revenue

World class Manufacturing facilities



Gajraula

Uttar Pradesh, India

Integrated facility for
Specialty Chemicals &
Chemical Intermediates

463 acres



Bharuch

Gujarat, India

CDMO & Fine Chemicals
Nutrition and Chemical
Intermediates

310 acres



Nira

Maharashtra, India

Chemical Intermediates
Facility

144 acres



Savli

Gujarat, India

Animal Nutrition
& Health Solutions Facility

109 acres



Ambarnath

Maharashtra, India

Microbial Control
Solutions Facility

3.5 acres

2300+ people

130+ products

1500+ customers

Operational Capabilities

Multi-Chemistry,
Multi-Product
Expertise

Continuous & Batch
processes

World Class cGMP
facility; US FDA
inspected

Responsible Care, TfS
commitment;
Ecovadis Gold

Ecologically
Harmonized Practices

Health & Safety
benchmarking global
performance

Significant investments in R&D and Innovation



R&D Center G. Noida UP, India



Pilot Plant at Gajraula UP, India

3
R&D Centers

~150
Scientists

~30
PhDs

Experienced and Energized Executive Leadership Team



SS Bhartia
Chairman



HS Bhartia
Co-Chairman & Whole
Time Director



Deepak Jain
CEO & MD
20 yrs exp

Business Leaders

Specialty Chemicals



Ambrish Dixit
President, Head of
Specialty Chemicals
24 yrs exp



Yuvraj B
Business Head
CDMO
18 yrs exp



Anurag Krishan
Business Head
Fine Chemicals
19 yrs exp



Amit Saini
Business Head
Pyridine & Picolines
21 yrs exp

Nutrition & Health



Ashish Kr. Sinha
Business Head Animal
& Human Nutrition
25 yrs exp



Rishi Gangwar
Business Head
Nutrition & Health Ingredients
21 yrs exp



Vishal Kadam
Business Head
Human Nutrition
27 yrs exp

Chemical Intermediates



Himanshu Dhapola
Business Head Acetyls
22 yrs exp

Function Leaders



Varun Gupta
President, Chief
Financial Officer
20 yrs exp



Birajeev Singh
Head of Supply Chain
23 yrs exp




**Parthasarathy
Basu**
Head of Strategy
and M&A
17 yrs exp



Sanjeev Kumar
Head of Quality &
Regulatory Affairs
26 yrs exp



Vijay Kumar Srivastava
President, Chief of Operation
& Whole Time Director
24 yrs exp



Vinita Koul
Head of HR
27 yrs exp

Growth Roadmap

(Recap and Progress
Update)

We set out on an ambitious growth path – Pinnacle 345

PINNACLE 3.4.5

3 times
REVENUE



4 times
EBITDA



5 year
HORIZON



PINNACLE 3.4.5

G R O W T H P I L L A R S

★ New Growth Areas

A

Specialty Chemicals

Pyridine & Picoline

Retain Global leadership (#1 position, cost leadership)



Scale up Oilfield chemicals

Fine Chemicals

P&P derivatives: Maintain leadership position

Diketene derivatives: Expand portfolio; Top 3 globally



Cosmetics/Microbial: Rapid Scale-up; leverage customer/products

CDMO

Pharma & Agro: Rapid Scale-up - Europe/US/Japan



Semi-con: Rapid scale-up; new technologies through partnerships

B

Nutrition & Health solutions

Animal Nutrition

Feed Vit B3: Extend global leadership position

Feed Vit B4: Consolidate domestic leadership

Pre-mixes: Leadership in India and neighboring markets

Human Nutrition

Cosmetic/Food grade B3: Rapid Scale-up

Choline Salts: Anchor products for food segment



Foray into Premix / other vitamins

C

Chemical Intermediates

Acetic Anhydride

Maintain global leadership position in merchant market

Optimize cost structure

Other Products

(Ethyl Acetate, Acetaldehyde, Bio-Acetic Acid, Propionic Anhydride)

Continue to scale in focused markets/ customers

Optimize cost structure

D

ENABLERS

Customer-first approach
(Key Account Mgmt)

World-class Ops
Best-in-class on Safety,
Quality, ESG

Deep R&D & Tech focus

Digital transformation






Agile Supply Chain

People / Org


Our Pinnacle journey in last one year: Good momentum across our key businesses...

Business	Key Achievements
Pyridine & Picoline	<ul style="list-style-type: none"> • Maintained global leadership and market share in Pyridine and Beta-Picoline • Increased SOW in AP/APQ across customers
Fine Chemicals	<ul style="list-style-type: none"> • 15%+ revenue growth in FY25; Maintained leadership across 36 Pyridine Derivatives • Good traction in Diketene Derivative with high utilization levels; capacity debottlenecking/expansion already initiated for new products • Expanded Cosmetic portfolio with good initial traction with key MNC customers
CDMO	<ul style="list-style-type: none"> • Pharma: 2x funnel expansion; good traction with innovators and tier-1 CDMOs across EU/US/Japan • Agro: 2 scale contracts with innovators; multiple other discussions in different stages • Semicon: 12+ opportunities in funnel; investments in R&D and dedicated team
Nutrition	<ul style="list-style-type: none"> • B3: Maintained leadership in feed; ramp-up in cosmetic and food grade with new plant commissioning • Animal Nutrition: 15% revenue growth in FY25; High traction in exports markets including Europe; specialty portfolio growth at 16% • Human Nutrition: Dedicated team, ramp-up in CC/CBT with marquee customers and in process of launching premixes; 2-3 more human grade products in pipeline
Acetyls	<ul style="list-style-type: none"> • Retained market share in both Domestic and Europe market for Acetic Anhydride • Increase in volumes across other key products: Ethyl Acetate and Acetaldehyde • Continuous focus on cost optimization and capacity Debottlenecking

...enabled through significant progress across our key capability pillars (not exhaustive)

Pillars	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26
 Customer	Roadshows across EU/ US/ Japan; 120+ customer meetings; introduction to new strategy and priorities	Secured CDMO order from Agro Innovator #1 Forayed into Semiconductor chemicals	Secured CDMO order from Agro Innovator #2 (\$300M)	Funnel expansion across Pharma/Agro/Semicon CDMO/FC/Nutrition opportunities; 70+ high priority funnel	In-process of launching of Human Nutrition pre-mixes Ramp-up of Cosmetic Grade Nia (new customers)
 R&D Focus	Streamlining of R&D pipeline to align with Pinnacle priorities; 40+ focused projects	Development of 8-10 new products	Leadership Hiring: Senior VP- R&D joined	Established dedicated team to optimize VC for existing and pipeline products	Expanded the team to 150+ scientists; build out of Human Nutrition R&D
 Operations	Bharuch GMP: USFDA audit with zero 483 Lean acceleration: 120+Cr\$ of savings	Roll out of productivity, energy and efficiency initiatives across sites	Launched dedicated Technology Cell Commissioned- Cosmetic Grade Niacinamide Facility	Received WEF Lighthouse award	First batch delivered for Agro Innovator #1 CDMO Lean 2.0 launched with 100cr+ savings target Integrated GenAI across R&D and other functions
 ESG/ Safety	Launch of 5S Program Expansion of Project Apollo	Increased thrust on Safety Program	Launch of new program in Process Safety Mgmt	Eco Vadis and DJSI ratings British Safety Awards O2 contract in Bharuch	Launch of new program in Transporters Safety Mgmt
 People/ Org	Streamlining of top org structure to bring more agility and focus on Pinnacle priorities	New CFO and SCM Head joined	Technology Cell Head Joined	BD teams expansion in Japan and Europe Human Nutrition Head joined Great place to work certified	New Projects Head joined

Q1'FY26 Highlights



Market Overview Q1'FY26 : Volumes gradually recovering across segments, though short-term tariff related uncertainty remains

PHARMA

- Volumes remained steady across segments, especially in our core products in Fine Chemicals
- The paracetamol segment remained muted given the low demand and utilization levels.
- Prices remain stable (vs Q4'FY25) across various segments; Customers awaiting clarity on tariff situation

AGROCHEM

- Agrochemical volumes grew both globally and in India; Pyridine-based Agrochemical products experienced a steady recovery in volumes
- Prices in Pyridine & Picolines products experienced short-term volatility after seeing stability through FY25

NUTRITION

- Choline (B4) demand remained steady; Positive tailwinds due to EU tariffs in coming quarters for non-Chinese players
- Niacinamide end-demand remained steady although customers delayed offtake, preferring to reduce inventory levels

Key business highlights Q1'FY26

Core product platforms continue to drive performance; Acetyls portfolio saw some recovery with increasing momentum across AA and EA products

- **Pyridine & Picoline:** Globally #1 position in P&P (only scaled non-Chinese player), QoQ volume growth driving overall sales growth despite some price volatility
- **Niacinamide:** Maintained leadership position in feed grade with improving realizations driven by increasing cosmetic grade sales on YoY and QoQ basis; Nia cosmetic grade plant stabilizing
- **Choline:** Maintained #1 position in Dry CC domestic market; Volumes grew QoQ and YoY
- **Acetyls:** Retained market share in Acetic Anhydride with QoQ volume growth; EA volumes grew YoY

Steady share of Specialty & Nutrition; Improved customer traction driving robust pipeline

- **63% revenue share & 90% EBITDA share** of Specialty & Nutrition in portfolio
- **KAM program showing traction with higher inbound queries across** CDMO Pharma, Agro and Semicon; 70+ high priority opportunities in funnel

Increasing revenue share from US & ROW; short-term volume drop in EU

- **US Revenue grew 11% YoY while ROW revenue grew 45% YoY driven by Spec Chem and Nutrition**
- **EU volumes saw short-term impact** driven by reduced offtake across Spec Chem & Nutrition
- **Continued push on Key Accounts yielding traction** in terms of bigger pipeline; BD team expansion across US, EU & Japan

Unlocking efficiency; continuous focus on Safety, ESG and 5S

- **Lean 2.0 cost reduction initiatives underway:** target of realizing **100cr+ savings**
- **Initiated GenAI usage at R&D** to bring agility in pipeline and product development
- **Safety, ESG and 5S programs on track**

Continuous investments for future growth

- **Capex completed** and first batch delivered for one Agro CDMO order
- **Capex on-track** for the \$300M Agro order; **Bharuch new boiler** slated to be commissioned in Q2
- **Debottlenecking activities ongoing to unlock** capacities for core platforms (diketene, pyridine)
- Detailed engineering initiated for the **new MPP plant in Gajraula**

Financial Results Overview | Q1'FY26 Consolidated

Particulars ¹	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Total Revenue	1,024	1,051	1,038	-1%	1%
Total EBITDA	119	155	153	-1%	29%
EBITDA Margin (%)	12%	15%	15%		
Profit After Tax	49	74	75	1%	54%
Profit After Tax Margin (%)	5%	7%	7%		
Basic and Diluted EPS (Rs.)	3.1	4.7	4.7	1%	54%

Revenue & EBITDA during the quarter was impacted on account of :



Specialty Chemicals

QoQ volume growth in Pyridine and its derivatives

Diketene derivatives - continued traction


YoY funnel growth in CDMO portfolio across Agro, Pharma and Semi-con



Nutrition & Health Solutions

Choline volumes – YoY & QoQ volume growth seen


Niacinamide realizations improved YoY & QoQ with higher cosmetic grade sales; Feed prices seeing some volatility



Chemical Intermediates

Acetic Anhydride volumes grew driven by recovering agro-demand but prices remained muted

EA prices continue to be at lower end of spectrum however volume push continued




Lower Input costs

Lower RM costs coupled with impact of Lean initiatives helped in increasing competitiveness and expanding margins

1. All figures are in Rs Crore unless otherwise stated

Highest Q1 EBITDA margin of 14.8% over last four years

JVL EBITDA




Key Drivers

- **Increasing revenue share of Specialty Chem + Nutrition BUs**
- **Increasing share of high-value products within each BU portfolio** e.g., increasing share of cosmetic/food grade B3, higher growth from new Diketene products, etc.
- **Cost measures:** Lean 2.0 initiatives across energy, operational efficiency, supply chain and overheads

Portfolio Shift: Spec Chem and Nutrition continue to drive EBITDA; Chemical Intermediates share inching with marginal recovery

Segment-wise EBITDA Share (%)




EBITDA trends: Secular YoY EBITDA growth in Spec Chem; stable margins in Nutrition despite short-term order pushouts; marginal recovery in Acetyls

Specialty Chemicals

EBITDA (Rs Cr.)

Y.o.Y Growth 52%
Q.o.Q Growth 1%




- **Notable increase in the volumes** of Pyridine derivatives, Diketene derivatives on QoQ basis
- **CDMO sales increased** on both QoQ and YoY basis driven by better mix and higher YoY volumes

Nutrition

EBITDA (Rs Cr.)

Y.o.Y Growth 8%
Q.o.Q Growth -16%




- **YoY growth in Nutrition sales and volumes** led by Choline
- QoQ performance led by **Niacinamide pricing pressures** and lower volumes led by order-pushouts

Chemical Intermediates

EBITDA (Rs Cr.)

Y.o.Y Growth -53%
Q.o.Q Growth 63%



- **QoQ growth** driven by shift in product mix and cost savings initiatives
- **YoY variance** due to **price erosion** from LY; Overall Acetyls volumes grew YoY

% EBITDA Margins – Before adjustment of Unallocated corporate expense/Income



Business Segments Overview



Specialty Chemicals | Market, Business & Financial Highlights

MARKET HIGHLIGHTS



- Continued improvement in demand observed
- YoY demand growth remained strong
- Steady pricing trend maintained



- Volumes showed modest, gradual growth
- Stable pricing trend observed
- Inventory levels stabilizing post-destocking



- Increased traction from customers across Pharma, Agro and semi-conductor segments, driven by supply chain diversification imperatives
- Traction with cosmetics and nutrition customers as well

FINANCIAL HIGHLIGHTS

Particulars ¹	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	431	487	478	-2%	11%
% Share of Overall Revenue	42%	46%	46%		
EBITDA	86	129	130	1%	52%
% EBITDA Margin	20%	27%	27%		
% Contribution to EBITDA ²	59%	76%	76%		

BUSINESS DRIVERS

- Segment revenue growth was led by higher Fine Chemicals and CDMO sales
- Margins continued to remain elevated on account of :
 - Higher sales from high margin orders within Specialty portfolio
 - Steady pricing in select Pyridine and Diketene Derivatives
 - Continuous cost optimizations measures undertaken

1. All figures are in Rs Crore unless otherwise stated.
2 Before adjustment of Unallocated corporate expense/Income

Nutrition & Health Solutions | Market, Business & Financial Highlights

MARKET HIGHLIGHTS



- Volumes were low as buyers delayed shipments, opting to maintain lower inventory levels
- Overall Pricing witnessed modest softening



- Cosmetic-grade demand surged on both QoQ and YoY basis
- New cGMP facility receiving exceptional response
- Steady sequential growth in food grade volumes



- Sustained strong YoY volume traction
- EU's anti-dumping duty on China, to boost Jubilant's competitive edge in Choline Chloride

FINANCIAL HIGHLIGHTS

Particulars ¹	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	186	190	179	-6%	-4%
% Share of Overall Revenue	18%	18%	17%		
EBITDA	23	29	25	-16%	8%
% EBITDA Margin	12%	16%	14%		
% Contribution to EBITDA ²	16%	17%	14%		

BUSINESS DRIVERS

- Revenue saw a modest decline, impacted by lower Niacinamide prices and shipment delays as customers opted for lean inventories
- YoY increase in Choline Chloride volumes and animal nutrition specialty business
- The sequential drop in EBITDA was mainly driven by lower volumes and prices of Niacinamide

1. All figures are in Rs Crore unless otherwise stated.

2 Before adjustment of Unallocated corporate expense/Income

Chemical Intermediates | Market, Business & Financial

3 Highlights

MARKET HIGHLIGHTS



- Acetic Anhydride volumes saw an uptick during the quarter driven by recovery in agrochem segments
- Ethyl Acetate volumes remained a key area of strategic emphasis



- Acetic Acid prices declined marginally during the quarter
- Through ongoing cost optimization measures and easing freight rates, margin expansion expected in few quarters



- Segment prices remained steady on a sequential basis

FINANCIAL HIGHLIGHTS

Particulars ¹	Q1'FY25	Q4'FY25	Q1'FY26	Q-o-Q	Y-o-Y
Segment Revenue	408	375	381	2%	-7%
% Share of Overall Revenue	40%	36%	37%		
EBITDA	36	10	17	63%	-53%
% EBITDA Margin	9%	3%	4%		
% Contribution to EBITDA ²	25%	6%	10%		

BUSINESS DRIVERS

- Revenue improved QoQ, supported by an increase in Acetic Anhydride volumes
- EBITDA improved sequentially, supported by higher Acetic Anhydride volumes and a slight reduction in input costs for Acetic Acid.

1. All figures are in Rs Crore unless otherwise stated.
2. Before adjustment of Unallocated corporate expense/Income

Annexures

Annexure I - Income Statement | Consolidated – Q1'FY26

Particulars ¹	Q1'FY25	Q4'FY25	Q1'FY26	QoQ	YoY
Revenue from operations					
a) Sales/Income from operations	1010	1038	1029	-1%	2%
b) Other operating income	14	13	9	-35%	-39%
Total revenue from operations	1024	1051	1038	-1%	1%
Other income	10	8	11	34%	17%
Total income	1034	1060	1049	-1%	1%
Expenses					
a) Cost of materials consumed	532	481	449	-7%	-16%
b) Purchases of stock-in-trade	7	32	32	1%	338%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	-11	20	38	94%	-453%
d) Employee benefits expense	102	96	108	13%	6%
e) Finance costs	14	14	13	-9%	-11%
f) Depreciation and amortisation expense	39	39	41	4%	5%
g) Other expenses:					
- Power and fuel expense	118	104	100	-4%	-15%
- Others	166	171	168	-2%	1%
Total expenses	968	958	949	-1%	-2%
Profit before share of loss of an associate (3-4)	66	102	100	-2%	51%
Share of loss of an associate	0		0		
Profit before tax	66	102	100	-2%	51%
Tax expense					
- Current tax	12	25	23	-8%	86%
- Deferred tax charge	5	2	2		
Net profit for the period/year	49	74	75	1%	54%
Earnings per share of ₹ 1 each					
Basic (₹)	3.1	4.7	4.7		
Diluted (₹)	3.1	4.6	4.7		

1. All figures are in Rs Crore unless otherwise stated.

Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others

Annexure II: Income Statement Segmental – Q1'FY26

Particulars ¹	Q1'FY25	Q4'FY25	Q1'FY26	QoQ (%)	YoY (%)
Revenue					
Speciality Chemicals	431	487	478	(2%)	11%
Nutrition & Health Solutions	186	190	179	(6%)	(4%)
Chemical Intermediates	408	375	381	2%	(7%)
Total Revenue from Operations	1,024	1,051	1,038	(1%)	1%
Reported EBITDA	119	155	153	(1%)	29%
Speciality Chemicals	86	129	130	1%	52%
Nutrition & Health Solutions	23	29	25	(16%)	8%
Chemical Intermediates	36	10	17	63%	(53%)
Unallocated Corporate & One-Off (Expenses)/Income	-25	-14	-19	-	-
PAT	49	74	75	1%	54%
EPS	3.1	4.7	4.7	1%	54%
Reported EBITDA Margins	12%	15%	15%		
Speciality Chemicals	20%	27%	27%		
Nutrition & Health Solutions	12%	16%	14%		
Chemical Intermediates	9%	3%	4%		
Net Margin	5%	7%	7%		

1. All figures are in Rs Crore unless otherwise stated.

Annexure III: Debt Position| As on 30th June 2025



Particulars ¹	30-Jun-24	31-Mar-25	30-Jun-25
Long Term Borrowings	450	453	448
Short Term Borrowings	291	303	360
Total Gross Debt	741	756	808
Cash & Equivalent	64	98	107
Total Net Debt	677	658	700
YoY change			3%

- The capex for the quarter was Rs 54 Crore, which was primarily utilized towards the upcoming CDMO Plant at Bharuch.

For More Information

Thank you for your time

Jubilant Ingrevia Limited is a globally integrated Life Sciences & Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad portfolio of over 130+ products and customized solutions that are innovative, cost-effective and conform to global quality standards.

It has over 40 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharma, agrochemicals and semi-conductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50 plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ over 145 scientists working on cutting-edge research and innovation.

Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies.

For more information, please visit: www.jubilantingrevia.com

For Investors:

Pavleen Taneja

Jubilant Ingrevia Limited.

☎ Ph: +91 120 436 1000

✉ E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar, CDR India

☎ Ph: +91 22 6645 1209

✉ E-mail: siddharth@cdr-india.com

☎ **For Media:**

✉ **Sandipan Ghatak**

Ph: +91 120 436 1062

E-mail: sandipan.ghatak@jubl.com